Let’s dive into all the details investors in ABSI stock need to know about that deal below!
- The agreement will have it providing Merck with its AI-powered Integrated Drug Creation Platform.
- This will be used to propel forward research in drugs of Merck’s choosing.
- That includes making use of Absci’s amino acid technology to create enzymes built for Merck’s biomanufacturing applications.
- The company will receive both upfront and milestone payments for this work.
- In addition to that, Merch can choose “three targets and enter into a drug discovery collaboration agreement.”
- That would net Absci $610 million in upfront fees and milestone payments for all three choices.
- It also opens the company up to “research funding and tiered royalties on sales.”
Sean McClain, founder and CEO of Absci, said the following about the deal boosting ABSI stock higher today.
“We are very pleased to establish this collaboration with Merck and to be working with its world class research organization to generate novel enzymes. We look forward to applying our AI-driven platform to create new biologic candidates with the potential to meaningfully improve the lives of patients.”
Heavy trading is affecting ABSI stock today alongside news of the Merck deal. This has some 35 million shares on the move as of this writing. That’s well above the company’s daily average trading volume of 252,000 shares.
ABSI stock is up 31.1% as of Friday morning.
Investors looking for more stock news will want to stick around!
We’ve got all the most recent news that traders need to know about for Friday. Among that is what’s happening with Trump Stocks, Sonos (NASDAQ:SONO) winning a patent battle, and AMC Entertainment (NYSE:AMC) stock chatter. You can find all of that at the following links!
More Friday Stock Market News
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed